HemaSphere is the official online, open access journal of the European Hematology Association (EHA). HemaSphere publishes exciting basic, translational, and clinical research in hematology. We are pleased to introduce our new podcast series where our host and guest speakers exchange ideas about select HemaSphere publications. Spend some time with us and enjoy casual and insightful discussions about hematology research. Listen to the stories behind the papers. HemaSphere is always accessible; our full range of open access publications is available at www.hemaspherejournal.com.
HemaSphere Podcast
Claim This Podcastby HemaSphere Journal
5.0(3 reviews)
28 episodes
Updated Bi-weekly
Accepts GuestsHas SponsorsLocation 🇪🇺
31
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality19
Social0
YouTube74
Engagement32
Podcast Overview
HemaSphere is the official online, open access journal of the European Hematology Association (EHA). HemaSphere publishes exciting basic, translational, and clinical research in hematology. We are pleased to introduce our new podcast series where our host and guest speakers exchange ideas about select HemaSphere publications. Spend some time with us and enjoy casual and insightful discussions about hematology research. Listen to the stories behind the papers. HemaSphere is always accessible; our full range of open access publications is available at www.hemaspherejournal.com.
Language
🇺🇲
Publishing Since
6/8/2023
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
31
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality19
Social0
YouTube74
Engagement32
6
Excellent Areas
2
Good Performance
11
Growth Opportunities
excellent
Episode Length
31 minutes
Performing excellently!
good
Show Experience
22 episodes over 2.2 years
Recommendations available
Unlock the full report to see detailed tips
poor
Publishing Consistency
Every 37 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
Reach the team behind HemaSphere Podcast
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
June 17, 2026
Why Inflammatory Signaling Holds the Key to Durable MDS Therapies - Dr Manja Wobus, Dr Katja Sockel
<p>In this episode, host Dr Charles de Bock delves into groundbreaking preclinical research exploring the potential of tasquinimod to restore blood cell production and modify the bone marrow microenvironment in MDS with Dr Manja Wobus and Dr Katja Sockel. Join us as we unpack the mechanisms, animal studies, and future clinical prospects for this promising therapy.</p><p>Read the accompanying article published in HemaSphere <a href="https://bit.ly/3OjuuiS" rel="noopener noreferrer" target="_blank">https://bit.ly/3OjuuiS</a></p><p>i4MDS, EHA's Specialized Working Group information <a href="https://hsphere.pub/5d4" rel="noopener noreferrer" target="_blank">https://hsphere.pub/5d4</a></p>
May 7, 2026
p53 in Cancer: Dual Threat - Dr Isabelle Plo, Dr Barbara Monte-Mór
<p>Discover the latest insights into the multifaceted role of p53 in normal hematopoiesis and its critical involvement in myeloproliferative neoplasms (MPNs). This episode features Dr. Isabelle Plo and Dr. Barbara Monte-Mór sharing their expertise on TP53 mutations, molecular mechanisms driving leukemic transformation, and emerging therapeutic strategies targeting p53.</p><p></p><p>Article: <a href="https://bit.ly/4sZbo01" rel="noopener noreferrer" target="_blank">https://bit.ly/4sZbo01</a></p><p></p><p>Comments, Suggestions or Feedback? Please take a few minutes and let us know: https://wkf.ms/4pDYjYb</p><p></p>
February 9, 2026
Blinatumomab in De Novo AYA ALL - Ep 4.2
<p>In this episode, host HemaSphere Scientific Editor Dr <strong>Charley de Bock</strong> speaks with <strong>Associate Professor Dr Matthew Greenwood</strong> about the <strong>SUBLIME (ALL09)</strong> trial, which explores replacing consolidation chemotherapy with <strong>blinatumomab</strong> in adolescents and young adults with B‑cell ALL. They discuss why immunotherapy may outperform traditional cytotoxic approaches, how MRD‑guided treatment is reshaping risk stratification, and what future protocols might look like as genomic and immune‑response data are integrated in real time. Dr. Greenwood also shares upcoming innovations—including menin inhibitors, venetoclax‑based MRD targeting, and adaptive platform designs—along with honest insights into the challenges of running clinical trials across Australia.</p>
28 total episodes available
Recent guests on HemaSphere Podcast
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Tim Mocking
Guest
Francesca Fioredda
Guest
Eleni Papadaki
Guest
Dr Francesca Tiso
Guest
Dr Florentien in 't Hout
Guest
Deep-dive analytics for HemaSphere Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is HemaSphere Podcast?
- How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 8 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.